Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 25 June to Question 61301 on Alzheimer's Disease: Drugs, if he will publish a (a) summary and (b) redacted version of the economic models used in the NICE appraisals of (i) lecanemab and (ii) donanemab.

The National Institute for Health and Care Excellence’s (NICE) single technology appraisal process relies on information provided by companies to evaluate the clinical and cost-effectiveness of new treatments. Some of this information, including the economic model, is considered commercially sensitive by the companies and is submitted to NICE in confidence. As a result, this material cannot be made publicly available. However, versions of the models with the commercially sensitive information redacted are available from NICE upon request, to registered stakeholders who have signed a confidentiality agreement, to inform their understanding of the evaluation.

NICE is committed to being as transparent as possible. While the economic models for lecanemab and donanemab cannot be published, the full committee papers, with confidential information redacted, are published. These contain a written description of the model design, inputs, and results. The appraisal committee’s consideration of the cost-effectiveness evidence is also documented in the published guidance. This ensures that stakeholders can understand the basis for NICE’s recommendations, even when certain technical details must remain confidential. The papers for lecanemab are available at the following link:

https://www.nice.org.uk/guidance/indevelopment/gid-ta11220/documents

In addition, the papers for donanemab are also available, at the following link:

https://www.nice.org.uk/guidance/indevelopment/gid-ta11221/documents